Oral Lactobacillus crispatus M247 as add-on prophylaxis for recurrent cystitis in women: a randomized pilot trial

Background Recurrent cystitis is common in women and drives repeated antibiotic exposure. We evaluated whether women supplemented orally with Lactobacillus crispatus M247 alongside Enterococcus faecium L3 plus Bifidobacterium animalis subsp. lactis BB-12 experienced fewer symptomatic cystitis recurrences than those receiving L3 plus BB-12 alone. Methods In this prospective, randomized, controlled, open-label, single-center exploratory pilot trial, 84 women with recurrent uncomplicated cystitis were allocated 1:1 to receive L. crispatus M247 for 90 days plus E. faecium L3 and B. animalis subsp. lactis BB-12 during the first 30 days (M247 add-on) or L3 plus BB-12 alone for 30 days. The primary outcome was the cumulative number of symptomatic cystitis recurrences per participant through 12 months after randomization. Recurrence status, patient-reported outcomes, adherence, tolerability, and safety were also assessed. Results All participants completed follow-up. By month 12, 19 recurrences occurred with M247 add-on and 46 with L3 plus BB-12 (0.45 ± 1.09 vs. 1.10 ± 1.56 episodes per participant; 58.7% relative reduction; p = 0.037). Seven of 42 women (16.7%) versus 15 of 42 (35.7%) experienced at least one recurrence, an absolute risk reduction of 19.0 percentage points (95% CI, 0.2–36.3; p = 0.047). At month 3, there were 2 versus 12 cumulative episodes (83.3% relative reduction; p = 0.022) and 2/42 (4.8%) versus 9/42 (21.4%) women with at least one recurrence (absolute risk reduction, 16.7 percentage points; 95% CI, 2.0–31.6; p = 0.024). Exploratory patient-reported findings included a lower Pelvic Pain and Urgency/Frequency (PUF) score at month 3 in the M247 add-on group (mean difference, −2.18 points; 95% CI, −3.12 to −1.24). All participants achieved at least 90% adherence; no serious adverse events or treatment discontinuations occurred. Conclusion In this exploratory pilot trial, M247 add-on supplementation was associated with a lower symptomatic cystitis recurrence burden than L3 plus BB-12 alone. Findings concerning urinary symptoms, sexual function, and quality of life are exploratory and remain susceptible to contextual and expectation-related effects. Confirmation in larger, double-blind, placebo-controlled multicenter trials is required. Clinical trial registration The trial is registered at ClinicalTrials.gov under identifier NCT06857565: https://clinicaltrials.gov/study/NCT06857565 .

Authors

Institutions

Publication Details

Journal
Frontiers in Nutrition
Published
2026-11-12
DOI
https://doi.org/10.3389/fnut.2026.1969675
Primary Topic
Urinary Tract Infections Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Oral Lactobacillus crispatus M247 as add-on prophylaxis for recurrent cystitis in women: a randomized pilot trial

M. O. Antipov, Daniela Caramazza, Chiara Maria Palazzi, Sara Mastrovito et al.
Frontiers in Nutrition
Urinary Tract Infections Management
article

Oral Lactobacillus crispatus M247 as add-on prophylaxis for recurrent cystitis in women: a randomized pilot trial

M. O. Antipov, Daniela Caramazza, Chiara Maria Palazzi, Sara Mastrovito, Giuseppe Campagna, Nikolay Ivanovich Briko, Andrea Lombisani, Lorenzo Vacca, Alfredo Ercoli, Franca Natale, Francesco Di Pierro, Andrea Carugno, Nicola Zerbinati, Anna Fagotti, Alexander Bertuccioli, Martino Recchia, Monia Marturano, Amjad Khan, Barbara Iurato
article en

Abstract

Background Recurrent cystitis is common in women and drives repeated antibiotic exposure. We evaluated whether women supplemented orally with Lactobacillus crispatus M247 alongside Enterococcus faecium L3 plus Bifidobacterium animalis subsp. lactis BB-12 experienced fewer symptomatic cystitis recurrences than those receiving L3 plus BB-12 alone. Methods In this prospective, randomized, controlled, open-label, single-center exploratory pilot trial, 84 women with recurrent uncomplicated cystitis were allocated 1:1 to receive L. crispatus M247 for 90 days plus E. faecium L3 and B. animalis subsp. lactis BB-12 during the first 30 days (M247 add-on) or L3 plus BB-12 alone for 30 days. The primary outcome was the cumulative number of symptomatic cystitis recurrences per participant through 12 months after randomization. Recurrence status, patient-reported outcomes, adherence, tolerability, and safety were also assessed. Results All participants completed follow-up. By month 12, 19 recurrences occurred with M247 add-on and 46 with L3 plus BB-12 (0.45 ± 1.09 vs. 1.10 ± 1.56 episodes per participant; 58.7% relative reduction; p = 0.037). Seven of 42 women (16.7%) versus 15 of 42 (35.7%) experienced at least one recurrence, an absolute risk reduction of 19.0 percentage points (95% CI, 0.2–36.3; p = 0.047). At month 3, there were 2 versus 12 cumulative episodes (83.3% relative reduction; p = 0.022) and 2/42 (4.8%) versus 9/42 (21.4%) women with at least one recurrence (absolute risk reduction, 16.7 percentage points; 95% CI, 2.0–31.6; p = 0.024). Exploratory patient-reported findings included a lower Pelvic Pain and Urgency/Frequency (PUF) score at month 3 in the M247 add-on group (mean difference, −2.18 points; 95% CI, −3.12 to −1.24). All participants achieved at least 90% adherence; no serious adverse events or treatment discontinuations occurred. Conclusion In this exploratory pilot trial, M247 add-on supplementation was associated with a lower symptomatic cystitis recurrence burden than L3 plus BB-12 alone. Findings concerning urinary symptoms, sexual function, and quality of life are exploratory and remain susceptible to contextual and expectation-related effects. Confirmation in larger, double-blind, placebo-controlled multicenter trials is required. Clinical trial registration The trial is registered at ClinicalTrials.gov under identifier NCT06857565: https://clinicaltrials.gov/study/NCT06857565 .

Frontiers in NutritionVol. 13
Università Cattolica del Sacro Cuore (IT), University of Insubria (IT), Liaquat University of Medical & Health Sciences (PK), Sechenov University (RU), University of Urbino (IT), Mario Negri Institute for Pharmacological Research (IT), Nuffield Orthopaedic Centre (GB), Agostino Gemelli University Polyclinic (IT), University of Oxford (GB), Velleja Research (IT), Policlinico Tor Vergata (IT)
Good health and well-being
Urinary Tract Infections Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon